Cytarabine
- Generic Name
- Cytarabine
- Brand Names
- Cytosar, Vyxeos
- Drug Type
- Small Molecule
- Chemical Formula
- C9H13N3O5
- CAS Number
- 147-94-4
- Unique Ingredient Identifier
- 04079A1RDZ
- Background
A pyrimidine nucleoside analog that is used mainly in the treatment of leukemia, especially acute non-lymphoblastic leukemia. Cytarabine is an antimetabolite antineoplastic agent that inhibits the synthesis of DNA. Its actions are specific for the S phase of the cell cycle. It also has antiviral and immunosuppressant properties. (From Martindale, The Extra Pharmacopoeia, 30th ed, p472)
- Indication
For the treatment of acute non-lymphocytic leukemia, acute lymphocytic leukemia and blast phase of chronic myelocytic leukemia.
Cytarabine is indicated in combination with daunorubicin for the treatment of newly-diagnosed therapy-related acute myeloid leukemia (t-AML) or AML with myelodysplasia-related changes (AML-MRC) in adults and pediatric patients 1 year and older.
- Associated Conditions
- Acute Lymphoblastic Leukemia (ALL), Acute Myeloid Leukemia, Acute Myeloid Leukemia With Myelodysplasia-Related Changes, Acute Promyelocytic Leukemia, Meningeal leukemia, Metastatic Malignant Neoplasm to the Leptomeninges, Non-Hodgkin's Lymphoma (NHL), Treatment-Related Acute Myeloid Leukemia, Blast phase Chronic myeloid leukemia
- Associated Therapies
- -
High-dose Cytarabine/Mitoxantrone Followed by Autotransplantation for t-MDS/t-AML
- Conditions
- Acute Myeloid LeukemiaMyelodysplastic Syndrome
- Interventions
- First Posted Date
- 2008-10-16
- Last Posted Date
- 2014-02-11
- Lead Sponsor
- University of Chicago
- Target Recruit Count
- 32
- Registration Number
- NCT00774046
- Locations
- 🇺🇸
The University of Chicago, Chicago, Illinois, United States
Risk-Adjusted Combination Chemotherapy in Treating Young Patients With Acute Lymphoblastic Leukemia
- Conditions
- Leukemia
- Interventions
- Drug: asparaginaseDrug: cyclophosphamideDrug: cytarabineDrug: dexamethasoneDrug: daunorubicin hydrochlorideDrug: doxorubicin hydrochlorideDrug: methotrexateDrug: mercaptopurineDrug: thioguanineDrug: etoposideDrug: vincristine sulfateDrug: ifosfamideDrug: leucovorin calciumDrug: prednisoneDrug: vindesine
- First Posted Date
- 2008-10-02
- Last Posted Date
- 2009-07-08
- Lead Sponsor
- University Hospital, Motol
- Target Recruit Count
- 4000
- Registration Number
- NCT00764907
- Locations
- 🇨🇿
University Hospital Motol, Prague, Czech Republic
Bortezomib, Daunorubicin, and Cytarabine in Treating Older Patients With Previously Untreated Acute Myeloid Leukemia
- Conditions
- Adult Acute Myeloid Leukemia With Inv(16)(p13;q22)Adult Erythroleukemia (M6a)Adult Pure Erythroid Leukemia (M6b)Acute Myeloid LeukemiaAdult Acute Monocytic Leukemia (M5b)Adult Acute Myeloblastic Leukemia Without Maturation (M1)Adult Acute Megakaryoblastic Leukemia (M7)Adult Acute Myeloid Leukemia With 11q23 (MLL) AbnormalitiesAdult Acute Myeloid Leukemia With t(16;16)(p13;q22)Adult Acute Minimally Differentiated Myeloid Leukemia (M0)
- Interventions
- First Posted Date
- 2008-08-28
- Last Posted Date
- 2014-09-12
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 95
- Registration Number
- NCT00742625
- Locations
- 🇺🇸
Wake Forest University Health Sciences, Winston-Salem, North Carolina, United States
🇺🇸University of North Carolina, Chapel Hill, North Carolina, United States
🇺🇸Virginia Commonwealth University, Richmond, Virginia, United States
Pilot Study of MGd + High-dose MTX-Based Chemoimmunotherapy + RT for Newly Dx PCNSL
- Conditions
- LymphomaNeurotoxicityBrain and Central Nervous System Tumors
- First Posted Date
- 2008-08-14
- Last Posted Date
- 2012-05-18
- Lead Sponsor
- Northwestern University
- Registration Number
- NCT00734773
Rituximab, Yttrium Y 90 Ibritumomab Tiuxetan in Patients W/Relapsed Stage II, III, or IV Follicular NHL
- Conditions
- Lymphoma
- Interventions
- Drug: MethylprednisoloneDrug: EtoposideDrug: CytarabineDrug: CisplatinDrug: RituximabDrug: In-ZevalinDrug: Y-Zevalin
- First Posted Date
- 2008-08-12
- Last Posted Date
- 2019-09-04
- Lead Sponsor
- University of Arizona
- Target Recruit Count
- 28
- Registration Number
- NCT00732498
- Locations
- 🇺🇸
The University of Arizona Cancer Center, Tucson, Arizona, United States
S0629, Observation or Combination Chemotherapy, Bortezomib, Thalidomide, and Rituximab Followed By Two Autologous Peripheral Blood Stem Cell Transplants in Treating Patients With Waldenstrom Macroglobulinemia
- Conditions
- Lymphoma
- Interventions
- Biological: rituximabDrug: bortezomibDrug: carmustineDrug: cisplatinDrug: cyclophosphamideDrug: cytarabineDrug: dexamethasoneDrug: doxorubicin hydrochlorideDrug: etoposideDrug: melphalanDrug: thalidomideProcedure: autologous-autologous tandem hematopoietic stem cell transplantationProcedure: peripheral blood stem cell transplantation
- First Posted Date
- 2008-07-29
- Last Posted Date
- 2015-03-06
- Lead Sponsor
- SWOG Cancer Research Network
- Registration Number
- NCT00723658
- Locations
- 🇺🇸
Saint Francis/Mount Sinai Regional Cancer Center at Saint Francis Hospital and Medical Center, Hartford, Connecticut, United States
🇺🇸St. Joseph Mercy Oakland, Pontiac, Michigan, United States
🇺🇸Sparrow Regional Cancer Center, Lansing, Michigan, United States
Dasatinib and Combination Chemotherapy in Treating Young Patients With Newly Diagnosed Acute Lymphoblastic Leukemia
- Conditions
- Acute Lymphoblastic LeukemiaAdult B Acute Lymphoblastic Leukemia With t(9;22)(q34.1;q11.2); BCR-ABL1Childhood B Acute Lymphoblastic Leukemia With t(9;22)(q34.1;q11.2); BCR-ABL1
- Interventions
- Drug: AsparaginaseDrug: CyclophosphamideDrug: CytarabineDrug: DasatinibDrug: Daunorubicin HydrochlorideDrug: DexamethasoneDrug: EtoposideBiological: FilgrastimDrug: Hydrocortisone Sodium SuccinateDrug: IfosfamideOther: Laboratory Biomarker AnalysisDrug: Leucovorin CalciumDrug: MercaptopurineDrug: MethotrexateDrug: MethylprednisoloneDrug: PegaspargaseDrug: PrednisoneRadiation: Radiation TherapyDrug: Vincristine Sulfate
- First Posted Date
- 2008-07-22
- Last Posted Date
- 2020-04-13
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 63
- Registration Number
- NCT00720109
- Locations
- 🇺🇸
New York Medical College, Valhalla, New York, United States
🇺🇸UCLA / Jonsson Comprehensive Cancer Center, Los Angeles, California, United States
🇺🇸Valley Children's Hospital, Madera, California, United States
Donor Stem Cell Transplant in Treating Patients With Mantle Cell Lymphoma
- Conditions
- Lymphoma
- First Posted Date
- 2008-07-22
- Last Posted Date
- 2013-08-02
- Lead Sponsor
- Cancer Research UK
- Target Recruit Count
- 25
- Registration Number
- NCT00720447
Autologous Stem Cell Transplant for Neurologic Autoimmune Diseases
- Conditions
- Multiple Sclerosis TransplantChronic Inflammatory Demyelinating PolyneuropathyMyasthenia GravisRasmussen Subacute EncephalitisNeurologic Autoimmune DiseaseCIDP TransplantCentral Nervous System VasculitisAutoimmune DiseaseAutologous Transplant AutoimmuneMS Stem Cell Transplant
- Interventions
- Biological: Anti-Thymocyte GlobulinProcedure: Autologous Hematopoietic Stem Cell TransplantationDrug: CarmustineDrug: CytarabineDrug: EtoposideOther: Laboratory Biomarker AnalysisDrug: MelphalanProcedure: Peripheral Blood Stem Cell TransplantationDrug: PrednisoneProcedure: Syngeneic Bone Marrow Transplantation
- First Posted Date
- 2008-07-16
- Last Posted Date
- 2024-07-18
- Lead Sponsor
- Fred Hutchinson Cancer Center
- Target Recruit Count
- 53
- Registration Number
- NCT00716066
- Locations
- 🇺🇸
Fred Hutch/University of Washington Cancer Consortium, Seattle, Washington, United States
🇺🇸Swedish Medical Center-First Hill, Seattle, Washington, United States
🇺🇸Colorado Blood Cancer Institute, Denver, Colorado, United States
Clofarabine Plus Cytarabine Versus Conventional Induction Therapy And A Study Of NK Cell Transplantation In Newly Diagnosed Acute Myeloid Leukemia
- Conditions
- Acute Myeloid Leukemia
- Interventions
- First Posted Date
- 2008-06-24
- Last Posted Date
- 2021-08-10
- Lead Sponsor
- St. Jude Children's Research Hospital
- Target Recruit Count
- 324
- Registration Number
- NCT00703820
- Locations
- 🇺🇸
University of Chicago, Chicago, Illinois, United States
🇺🇸Stanford University Medical Center, Palo Alto, California, United States
🇺🇸St. Jude Children's Research Hospital, Memphis, Tennessee, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.